Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>Incyte's financial performance is dominated by its flagship drug, Jakafi, which is facing a patent cliff around 2028, creating significant long-term revenue risk.</li>
 <li>The company is actively pursuing a diversification strategy through the strong uptake of its dermatology cream, Opzelura, and by advancing a pipeline of novel oncology and inflammation therapies.</li>
 <li>Strategic acquisitions, such as the potential $2 billion deal for Star Therapeutics and its late-stage asset VGA039, are a key component of the strategy to mitigate the upcoming loss of exclusivity for Jakafi.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  Incyte's financial performance is dominated by its flagship drug, Jakafi, which is facing a patent cliff around 2028, creating significant long-term revenue risk.
  The company is actively pursuing a diversification strategy through the strong uptake of its dermatology cream, Opzelura, and by advancing a pipeline of novel oncology and inflammation therapies.
  Strategic acquisitions, such as the potential $2 billion deal for Star Therapeutics and its late-stage asset VGA039, are a key component of the strategy to mitigate the upcoming loss of exclusivity for Jakafi.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Incyte Corporation’s second quarter of 2026 performance reflects significant progress in diversifying its revenue base beyond its cornerstone product, Jakafi, while advancing multiple late-stage clinical programs across hematology, oncology, and immunology/inflammation franchises.</li><li>Total revenue increased 38% year-over-year to $1.67 billion, with total net sales of $1.49 billion, marking a 40% increase.</li><li>Excluding a one-time noncash benefit of $246 million from a CMS settlement related to Medicaid rebate litigation impacting Opzelura, net sales grew 17%.</li></ul>

Incyte Corporation’s second quarter of 2026 performance reflects significant progress in diversifying its revenue base beyond its cornerstone product, Jakafi, while advancing multiple late-stage clinical programs across hematology, oncology, and immunology/inflammation franchises.Total revenue increased 38% year-over-year to $1.67 billion, with total net sales of $1.49 billion, marking a 40% increase.Excluding a one-time noncash benefit of $246 million from a CMS settlement related to Medicaid rebate litigation impacting Opzelura, net sales grew 17%.

Incyte Corporation’s $450 Million Opzelura Franchise Unlocks A New Growth Engine!

European Event-Driven Analyst

Jesus Rodriguez Aguilar

Event-Driven

<ul>
<li>Novartis offers an agreed €68/share, 89% premium, for <a href="https://www.smartkarma.com/entities/morphosys-ag-91f7c8f8-f418-4db5-953e-ec2206d64e67" target="_blank" data-smartkarma-citation="entities:27120:1" rel="noopener">MorphoSys AG (MOR US)</a> in a bet that pelabrisib could become a blockbuster to treat myelofibrosis (possibly reaching peak sales of $1.1-1.5 billion).</li>
<li>Considering that the shares of Morphosys were trading in the low teens in November, I believe that shareholders will be happy to part with the shares.</li>
<li>Spread (gross/annualised) is 4.65%/18.09% (assuming settlement by 20 May). Novartis believes pelabrisib is definitely worth the risk. Long.
</li>
</ul>


Novartis offers an agreed €68/share, 89% premium, for MorphoSys AG (MOR US) in a bet that pelabrisib could become a blockbuster to treat myelofibrosis (possibly reaching peak sales of $1.1-1.5 billion).
Considering that the shares of Morphosys were trading in the low teens in November, I believe that shareholders will be happy to part with the shares.
Spread (gross/annualised) is 4.65%/18.09% (assuming settlement by 20 May). Novartis believes pelabrisib is definitely worth the risk. Long.



Novartis Strikes for Possible Myelofibrosis Blockbuster

<ul><li>Incyte Corporation is reportedly close to acquiring privately held Star Therapeutics in a transaction valued at up to $2 billion, including about $1.25 billion in upfront cash and $750 million tied to future milestones.</li><li>The deal would bring Star’s lead asset, VGA039, into Incyte’s portfolio at a critical point for the company.</li><li>VGA039 is a late-stage, once-monthly injectable therapy for von Willebrand disease, the most common inherited bleeding disorder, and has received FDA Fast Track designation.</li></ul>

Incyte Corporation is reportedly close to acquiring privately held Star Therapeutics in a transaction valued at up to $2 billion, including about $1.25 billion in upfront cash and $750 million tied to future milestones.The deal would bring Star’s lead asset, VGA039, into Incyte’s portfolio at a critical point for the company.VGA039 is a late-stage, once-monthly injectable therapy for von Willebrand disease, the most common inherited bleeding disorder, and has received FDA Fast Track designation.

Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore!

<ul><li>Incyte Corporation reported robust financial performance and strategic advancements in their fourth quarter and full-year 2025 results, illustrating both progress and challenges.</li><li>The company achieved significant sales growth, driven primarily by the strong performance of its flagship product, Jakafi, and substantial contributions from its core business excluding Jakafi.</li><li>Total revenues for the fourth quarter reached $1.51 billion, marking a 28% increase year-over-year, while full-year revenues grew by 21% to $5.14 billion.</li></ul>

Incyte Corporation reported robust financial performance and strategic advancements in their fourth quarter and full-year 2025 results, illustrating both progress and challenges.The company achieved significant sales growth, driven primarily by the strong performance of its flagship product, Jakafi, and substantial contributions from its core business excluding Jakafi.Total revenues for the fourth quarter reached $1.51 billion, marking a 28% increase year-over-year, while full-year revenues grew by 21% to $5.14 billion.

Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally?

United States

Incyte Corp is a biopharmaceutical company. The Company discovers, develops and commercializes proprietary small molecule drugs, primarily used in oncology.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Incyte Corp (INCY US)

Primer: Incyte Corp (INCY US) - Aug 2026

Incyte's financial performance is dominated by its flagship drug, Jakafi, which is facing a patent cliff around 2028, creating significant...

αSK Primers

Incyte Corporation’s $450 Million Opzelura Franchise Unlocks A New Growth Engine!

Incyte Corporation’s second quarter of 2026 performance reflects significant progress in diversifying its revenue base beyond its cornerstone...

Baptista Research

Novartis Strikes for Possible Myelofibrosis Blockbuster

Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...

Jesus Rodriguez Aguilar

Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore!

Incyte Corporation is reportedly close to acquiring privately held Star Therapeutics in a transaction valued at up to $2 billion, including about...

Baptista Research

Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally?

Incyte Corporation reported robust financial performance and strategic advancements in their fourth quarter and full-year 2025 results,...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Incyte Corp (INCY US) - Aug 2026

Incyte's financial performance is dominated by its flagship drug, Jakafi, which is facing a patent cliff around 2028, creating significant...

αSK Primers

Incyte Corporation’s $450 Million Opzelura Franchise Unlocks A New Growth Engine!

Incyte Corporation’s second quarter of 2026 performance reflects significant progress in diversifying its revenue base beyond its cornerstone...

Baptista Research

Novartis Strikes for Possible Myelofibrosis Blockbuster

​Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...

Jesus Rodriguez Aguilar

Incyte Buyout Bet: The $2 Billion Move Investors Can’t Ignore!

Incyte Corporation is reportedly close to acquiring privately held Star Therapeutics in a transaction valued at up to $2 billion, including about...

Baptista Research

Incyte’s Opzelura Opportunity Is Getting Bigger—How Much Upside Does Moderate AD Unlock Internationally?

Incyte Corporation reported robust financial performance and strategic advancements in their fourth quarter and full-year 2025 results,...

Baptista Research

Novartis offers premium for MorphoSys AG in a bet on pelabrisib as a potential blockbuster for myelofibrosis treatment. Shareholders are likely to...